Abstract
Bio-encoded nanostructures use nucleic-acid or protein sequence information to specify aspects of nanoscale assembly, ligand display, cargo organization, or stimulus-responsive function. Their pharmacological promise depends not only on whether a structure can be designed, but on whether the intended architecture survives manufacture and biological exposure, reaches the relevant compartment, produces target engagement, and does so with acceptable safety. This narrative review examines DNA and RNA nanostructures, self-assembling protein nanoparticles, virus-like particles, and selected biomimetic systems through a pharmacology-first lens. Rather than treating programmability as evidence of therapeutic superiority, it links design features to testable development questions: What product attributes must be measured? Which experiment can identify a failure in assembly, stability, biodistribution, intracellular delivery, or pharmacodynamic activity? What evidence is needed before a candidate advances? The review proposes a six-layer framework spanning molecular information, assembly, biological recognition, disposition, response, and translation, then converts it into a practical failure-analysis workflow with measurable readouts and decision points. The framework is a proposed development aid, not a validated predictive model or an established regulatory classification. Its value will depend on prospective testing against platform-specific datasets and demonstration that it improves experimental prioritization. By separating demonstrated findings from hypotheses and linking each design claim to an assay and a development decision, the review aims to help researchers more precisely diagnose translational bottlenecks and reduce the risk of advancing nanostructures based on in vitro programmability alone.